Telehealth ADHD Prescribing: What Psychiatric NPs Can Do in Michigan

If you’re a psychiatrist or PMHNP wondering whether you can treat ADHD patients online and prescribe stimulants through telehealth, the short answer is: yes, for now—but the rules are complicated and changing.

Let’s cut through the confusion. As a provider, you’re probably searching for clarity on:

• Can I legally prescribe Adderall or Ritalin through a video visit?
• What are the federal rules versus state rules?
• How does my scope of practice (MD vs NP) affect what I can prescribe?
• What happens when the current telehealth flexibilities expire?

This guide walks through exactly what psychiatrists and PMHNPs can do right now, what the law requires, and how to stay compliant while building a thriving telehealth ADHD practice.

The Federal Framework: Where We Stand in 2026

Here’s what matters most: ADHD medications like Adderall, Vyvanse, and Ritalin are Schedule II controlled substances, which means they’re tightly regulated by the DEA under the Ryan Haight Act. Normally, that law requires an in-person medical evaluation before a provider can prescribe any controlled substance via telemedicine.

But during COVID, that requirement was waived. The DEA allowed providers to prescribe stimulants through telehealth without ever meeting the patient face-to-face. That flexibility has been extended multiple times—most recently through December 31, 2025. As of early 2026, we’re in a grace period, but there’s no permanent rule in place yet.

What this means for you: Right now, you can conduct an initial ADHD evaluation via video, diagnose the condition, and e-prescribe stimulants—all without an in-person visit. But this is temporary. Unless Congress acts or the DEA implements new permanent rules, we could revert to requiring in-person exams in 2026 or 2027.

The DEA has floated the idea of a ‘special telemedicine registration’ that would allow providers to prescribe controlled substances remotely long-term, but nothing concrete has been finalized. Keep an eye on federal policy updates, especially from the DEA and HHS.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-Specific Rules: Where You’re Licensed Matters

Federal law sets the baseline, but state laws add another layer—and they vary significantly. Some states explicitly support telehealth prescribing of stimulants for psychiatric conditions. Others have additional restrictions.

States That Explicitly Allow Telehealth ADHD Prescribing

Florida is one of the clearest: Florida law allows telehealth providers to prescribe Schedule II controlled substances for psychiatric disorders, which includes ADHD. The statute carves out an exception specifically for mental health treatment, making it straightforward for psychiatrists to treat ADHD patients via video in Florida.

Texas doesn’t ban telehealth prescribing of stimulants for mental health, but it requires that the encounter be conducted via live video (not audio-only) and that it meets the same standard of care as an in-person visit. Texas also prohibits prescribing controlled substances via telemedicine for chronic pain management, but ADHD doesn’t fall under that restriction.

California, New York, Pennsylvania, and Illinois generally defer to federal guidelines—none of these states have laws prohibiting telehealth prescribing of ADHD medications as long as you’re complying with DEA rules. However, each state has its own licensing requirements, prescription monitoring mandates, and documentation standards you’ll need to follow.

Key State Requirements to Know

Prescription Drug Monitoring Programs (PDMPs): Most states require you to check the state PDMP before prescribing controlled substances. For example:

• New York mandates checking the I-STOP registry for every controlled substance prescription
• Texas encourages (but doesn’t legally require) checking the PMP for stimulants
• Florida requires consulting the EFORCSE database before prescribing Schedule II-IV drugs

E-Prescribing Mandates: Many states now require electronic prescribing for controlled substances:

• California mandated e-prescribing starting in 2022
• New York has required EPCS (Electronic Prescribing for Controlled Substances) since 2016
• Illinois implemented mandatory e-prescribing for controlled substances in January 2023

These aren’t barriers—most telehealth platforms have EPCS-compliant systems built in—but you need to be aware of them.

Psychiatrists vs PMHNPs: Who Can Prescribe What?

This is where things get really state-specific.

Psychiatrists (MD/DO): Full Authority Everywhere

If you’re a psychiatrist, you have unrestricted prescriptive authority in every state for ADHD medications. You don’t need supervision, collaboration agreements, or special permissions. Your only limits are the federal controlled substance rules and standard-of-care requirements.

You can:

• Diagnose ADHD via telehealth
• Prescribe any ADHD medication (stimulants or non-stimulants)
• Write 30-day prescriptions (standard practice)
• Manage care entirely through video visits

Your main compliance requirements:

• Valid medical license in the state where the patient is located
• DEA registration
• State controlled substance permit (if your state requires one)
• PDMP checks per state law
• Documentation that meets telehealth standards

PMHNPs: It Depends on Your State

If you’re a psychiatric nurse practitioner, your ability to prescribe ADHD stimulants varies dramatically by state.

Full Practice Authority States (After Experience):

New York: After completing 3,600 hours (about 2 years) of supervised practice, you can practice and prescribe completely independently, including Schedule II stimulants. During your initial period, you need a collaborative agreement with a physician, but most agreements allow stimulant prescribing.

Illinois: Once you complete 4,000 hours of clinical experience plus 250 hours of additional training, you can obtain Full Practice Authority and prescribe ADHD medications independently. Prior to that, you need a written collaborative agreement that explicitly delegates Schedule II prescribing authority.

California: The state is transitioning to NP independence through AB 890. Experienced NPs (≥3 years, 4,600 hours) can now apply for independent ‘104 NP’ status. However, you must complete a specific pharmacology course to prescribe Schedule II drugs. Until you reach independence, you need physician supervision.

Restricted Practice States:

Texas: This is the most restrictive. Texas law prohibits NPs from prescribing Schedule II controlled substances in outpatient settings except in hospitals, emergency departments, or hospice care. This means you cannot prescribe Adderall or other stimulants for routine ADHD patients. Only psychiatrists (MDs/DOs) can do this in Texas. You can still evaluate ADHD patients and manage non-stimulant medications (like Strattera or Wellbutrin), but stimulant prescriptions must come from a physician.

Florida: You need a supervisory protocol with a psychiatrist. Florida normally limits NPs to a 7-day supply of Schedule II drugs, but there’s a crucial exception: psychiatric nurses working under a psychiatrist’s protocol can prescribe psychotropic controlled substances beyond 7 days. So if you’re a PMHNP collaborating with a psychiatrist, you can prescribe 30-day supplies of ADHD stimulants. But you cannot practice independently.

Pennsylvania: You must have a collaborative agreement with a physician. PA law limits you to prescribing an initial 72-hour supply of Schedule II drugs for new patients or new conditions, after which you can prescribe 30-day supplies for ongoing therapy. The physician must be notified and involved in the care plan. This creates an extra workflow step compared to states where you can start patients on a full month of medication.

Bottom line: If you’re a PMHNP, check your state’s nurse practice act carefully. In some states, you’re essentially equal to a psychiatrist in prescribing power (once experienced). In others, you’ll need an MD partner or you simply cannot prescribe stimulants for outpatient ADHD care.

Clinical Workflow: How to Conduct ADHD Telehealth Evaluations Safely

The regulatory stuff matters, but let’s talk about the actual practice. How do you evaluate and treat ADHD via telehealth while staying compliant and providing quality care?

Initial Evaluation

A thorough ADHD assessment via video should mirror what you’d do in person:

1. Comprehensive psychiatric interview: DSM-5 criteria for ADHD require symptoms in multiple settings (work/school and home), present since childhood for adults, and causing significant impairment. You’ll need to document:

• Current symptoms (inattention, hyperactivity, impulsivity)
• Childhood history (many adults weren’t diagnosed as kids but had symptoms)
• Functional impairment (job performance, relationships, daily tasks)
• Collateral information if possible (though adult patients may not have this readily available)

2. Use standardized rating scales: Electronic questionnaires make this easy. Common tools include:

• ADHD Rating Scale (ADHD-RS)
• Adult ADHD Self-Report Scale (ASRS)
• Conners Adult ADHD Rating Scales

These help quantify symptoms and provide documentation for your chart.

3. Rule out other conditions: This is critical both clinically and for avoiding scrutiny. Make sure you’re screening for:

• Substance use (current or past)
• Mood disorders (depression and bipolar disorder can mimic ADHD)
• Anxiety disorders
• Sleep disorders
• Thyroid issues or other medical causes

Many patients seeking stimulants online may have undiagnosed bipolar disorder, substance use issues, or are looking to misuse medication. A careful differential diagnosis protects both you and the patient.

4. Assess cardiac risk: Stimulants can increase heart rate and blood pressure. You should:

• Ask about personal or family history of cardiac problems
• Have patients check baseline vital signs (many can use a pharmacy blood pressure cuff or home device)
• Consider requesting an EKG for patients over 40 or those with cardiac risk factors (though this isn’t universally required by guidelines)

Prescribing and Documentation

Once you’ve confirmed ADHD and ruled out contraindications:

Start conservatively: Begin with a low dose of a stimulant (e.g., 10mg Adderall IR twice daily or 18mg Concerta once daily) and titrate based on response and side effects.

Document thoroughly: Your note should clearly state:

• DSM-5 criteria met
• Rating scale scores
• Risk assessment (diversion risk, substance use history, psychiatric comorbidities)
• Informed consent discussion (including risks of stimulant therapy)
• Treatment plan and monitoring schedule

E-prescribe immediately: Send the prescription electronically through your EPCS system. Include clear directions and exactly 30 days’ supply (no refills on Schedule II—federal law).

Check the PDMP: Before prescribing and at regular intervals (at least every 3 months, or per your state’s requirement).

Follow-Up Care

Most ADHD patients on stimulants need monthly follow-ups, at least initially. You’re checking:

• Symptom improvement (using rating scales periodically)
• Side effects (appetite, sleep, anxiety, blood pressure)
• Adherence and proper use
• Need for dose adjustment

These visits can be brief (10-15 minutes) and are typically billed as 99213 or 99214 E/M codes. Medicare and most commercial insurers reimburse telehealth follow-ups at the same rate as in-person visits—around $89-95 for a 15-minute visit and $125-136 for a 25-minute visit.

Reimbursement: Will You Get Paid?

Here’s the good news: telehealth reimbursement for psychiatric medication management is strong in 2026.

Nearly all states have enacted some form of telehealth parity, meaning insurers must pay the same rate for virtual visits as in-person visits. Medicare extended its COVID-era telehealth coverage for mental health services and pays at non-facility rates for video visits. Private insurers generally follow suit.

Typical reimbursement rates for psychiatrists:

Medicaid rates are lower—often $40-65 for a med check—but most Medicaid programs now cover telehealth at parity with in-person care.

Psychiatrists are reimbursed at the highest rates for psychiatric services compared to other provider types because you hold a medical license. PMHNPs may see slightly lower reimbursement (about 85% of MD rates in Medicare if billing under their own NPI), but many practices find ways to bill at full rates through supervision arrangements.

The key point: you’re not leaving money on the table by doing telehealth. In fact, because you eliminate office overhead and can see patients more efficiently (no waiting room, less no-show issues when it’s just a video link), your net income per hour can actually be higher than traditional practice.

Real Practice Economics: What ADHD Telehealth Actually Looks Like

Let’s talk about what building an ADHD practice actually means financially.

The DIY Marketing Reality

Some providers think, ‘I’ll just market myself online and acquire patients directly.’ Here’s what that really costs:

SEO (Search Engine Optimization):

• Takes 6-12 months of consistent investment before generating meaningful patient flow
• Requires content creation, technical website optimization, link building
• Realistic cost: $2,000-5,000/month for professional help
• Most solo providers don’t have the expertise or patience for this

Google Ads:

• Mental health keywords are expensive: $15-40+ per click
• Conversion rates are typically 2-5% (meaning 20-50 clicks to get one booked patient)
• Realistic cost per booked patient: $200-400+ after accounting for wasted clicks, landing page optimization, ad management

Directory Listings:

• Psychology Today: ~$30/month but you compete with hundreds of other providers on the same page
• Zocdoc: Charges per booking ($35-100+ per patient) PLUS monthly subscription fees
• Headway, Alma, etc.: Take 10-15% of session revenue and still require you to manage your own marketing

Total Reality: If you’re acquiring patients through DIY marketing, you’re typically spending $200-500+ per patient when you factor in all costs—agency fees, ad spend, staff time to handle leads, no-shows from cold leads, months of investment with no results, and failed campaigns.

And that’s assuming you get it right. Most providers waste thousands on marketing that doesn’t work before figuring out what does.

The Platform Economics Alternative

This is where a platform like Klarity Health changes the equation.

Instead of gambling $3,000-5,000/month on marketing with uncertain results, you pay only when you actually see a patient. Klarity uses a pay-per-appointment model similar to Zocdoc, but with crucial differences:

• No upfront marketing spend or monthly subscriptions
• Pre-qualified patients already matched to your specialty and availability (no wasted time on leads that don’t convert)
• No ad budget waste on clicks that go nowhere
• Built-in telehealth infrastructure (no separate platform costs or tech headaches)
• Both insurance and cash-pay patient flow (diversified revenue streams)
• You control your schedule—only pay when you actually see patients

The standard listing fee per new patient lead is transparent and predictable. That’s guaranteed ROI: every dollar you spend brings an actual patient encounter, not just clicks or ‘maybes.’

Compare that to the alternative: spending $5,000/month on marketing, getting 15 booked patients (if you’re lucky), and netting maybe 10 who actually show up. That’s $500/patient vs. a fixed, known cost with Klarity—and you didn’t have to manage the marketing, field the leads, or worry about compliance in ad copy.

Provider Pain Points We Keep Hearing

Let’s address the real frustrations providers have with ADHD telehealth:

‘I’m Not Sure If I’m Compliant’

You’re not alone. The regulatory landscape is genuinely confusing—federal rules keep changing, state laws vary, and the consequences of getting it wrong are serious.

Solution: Work with platforms or practices that handle compliance infrastructure. Most telehealth-native companies have legal teams tracking every state’s requirements and ensuring their workflows meet standards. You focus on clinical care; they manage PDMP integration, EPCS setup, and documentation requirements.

‘Medication Shortages Are Killing My Practice’

Since late 2022, Adderall and other stimulant shortages have been a nightmare. Patients can’t fill prescriptions. Pharmacies are out of stock. You’re spending unpaid time coordinating alternatives.

Reality: This is a supply chain issue beyond any provider’s control. The DEA sets manufacturing quotas and they’ve been slow to adjust despite soaring demand.

Workarounds:

• Prescribe generic alternatives (different manufacturers may have stock)
• Have backup non-stimulant options ready (Strattera, Wellbutrin, Qelbree)
• Build relationships with compounding pharmacies in some states
• Help patients use pharmacy finder tools to locate available stock

This frustration is real, but the shortage has been gradually improving as the DEA has increased production limits in response to pressure from the FDA and medical organizations.

‘Every State Has Different Rules—How Do I Scale?’

If you want to practice in multiple states, you need licenses in each state. That means application fees, separate DEA registrations in some states, learning each state’s PDMP system, and tracking differing requirements.

For Psychiatrists: This is tedious but straightforward. Once licensed, you have full authority in that state.

For PMHNPs: This is genuinely harder because your scope changes state-to-state. You might be independent in New York but need a collaborator in Florida. Some platforms solve this by providing physician collaborators in restricted states so you can still practice there.

Practical approach: Start with 2-3 high-demand states where you’re already licensed or where licensing is streamlined (Interstate Medical Licensure Compact states, for example). Once you have patient flow, expand strategically.

Market Opportunities by State

Demand for ADHD telehealth varies significantly by state due to provider supply and population factors:

Texas and Florida: Severe Shortages

• Texas: ~1 psychiatrist per 9,000 residents (43rd in the nation)
• Florida: ~1 per 8,577 residents (42nd)
• These states desperately need providers, but restrictive NP laws mean you need MDs to prescribe stimulants
• Huge opportunity for psychiatrists; PMHNPs will need collaborative arrangements

New York: Saturated in Cities, Shortage Upstate

• NYC has ~1 psychiatrist per 2,900 residents (excellent)
• But rural upstate counties have almost none
• Competition is high in the city; opportunity exists in serving underserved regions via telehealth
• NP-friendly laws mean PMHNPs can practice independently after 2 years

Pennsylvania: Moderate Supply, Regulatory Friction

• ~1 psychiatrist per 4,586 residents (slightly better than average)
• NP restrictions (72-hour initial prescriptions) create workflow challenges
• Rural areas still underserved despite decent overall numbers

Illinois: Growing NP Independence

• ~1 per 5,849 residents (moderate)
• Chicago metro well-served; downstate struggling
• Full Practice Authority for experienced NPs is expanding the provider pool
• Telehealth strongly supported by state policy

California: Competitive but Enormous Market

• ~1 per 5,636 residents (average)
• Huge population (40 million) means massive demand despite many providers
• NP autonomy expanding rapidly under AB 890
• High reimbursement rates in metro areas

What Happens If Federal Rules Change?

This is the elephant in the room. What if the DEA’s temporary telehealth flexibilities expire and we revert to requiring in-person exams?

Scenario 1: Congress passes permanent telehealth prescribing authority

• Most likely outcome given bipartisan support for telehealth access
• Would allow continued prescribing without in-person requirements
• Probably include some guardrails (ID verification, specific documentation standards)

Scenario 2: DEA implements ‘special registration’ for telemedicine

• Providers apply for a specific authorization to prescribe controlled substances via telehealth
• Likely requires additional training, monitoring, or compliance standards
• Would create a clear legal pathway for long-term telehealth prescribing

Scenario 3: Reversion to Ryan Haight Act requirements

• Would require at least one in-person exam before prescribing controlled substances via telemedicine
• Most disruptive scenario, but also least likely given political and public pressure
• Platforms would adapt by partnering with local clinics for initial exams, then continuing care via telehealth

What you should do: Don’t panic, but have a contingency plan. If you’re building a telehealth-only practice, consider how you’d arrange in-person evaluations if needed (partnerships with urgent cares, local clinics, or hybrid models). The most likely outcome is that telehealth prescribing authority continues in some form—the COVID-era experience proved it works, demand is too high to ignore, and provider shortages are too severe.

Best Practices to Avoid Scrutiny

The DEA and state medical boards have cracked down on some telehealth companies that were overprescribing stimulants with minimal evaluation. Don’t be the next cautionary tale.

Red flags that attract attention:

• Prescribing stimulants after 5-minute ‘consultations’
• No documentation of diagnostic criteria
• Ignoring red flags (substance use history, diversion risk, ‘lost’ prescriptions)
• Prescribing to patients outside your licensed states
• Not checking PDMPs

How to practice defensively:

• Document thoroughly: Every ADHD diagnosis should have clear DSM-5 criteria documentation, rating scale scores, and differential diagnosis considerations
• Use rating scales: They provide objective measures and improve your documentation
• Set clear boundaries: If a patient’s story doesn’t add up or they’re demanding specific doses/medications, it’s okay to decline or require further evaluation
• Regular monitoring: Monthly visits initially, then every 2-3 months once stable. Don’t just write refills without patient contact
• Collaborate with PCPs: When possible, communicate with the patient’s primary care doctor. It shows coordinated care and reduces risk
• Consider urine drug screens: For patients with substance use history or when you have concerns, periodic UDS is reasonable (though challenging to arrange in pure telehealth)
• Patient agreements: Use treatment agreements that outline expectations, pill counts, single prescriber/pharmacy policies

Why Join a Platform vs. Going Solo?

You might be thinking: ‘Why not just hang my own shingle online?’

Solo practice advantages:

• Keep 100% of revenue (minus payment processing)
• Complete control over branding and patient experience
• No platform fees

Solo practice reality:

• You handle all marketing (expensive and time-consuming)
• You manage all compliance and credentialing (complex across multiple states)
• You build your own telehealth infrastructure (or pay for multiple platforms)
• You handle billing, collections, no-shows, patient support
• It takes 12-18 months to build meaningful patient volume through organic growth

Platform advantages (like Klarity):

• Instant patient flow: Start seeing patients within weeks of credentialing, not months
• No marketing risk: You’re not gambling thousands on ads that might not work
• Compliance infrastructure: PDMP integration, EPCS, documentation templates already built
• Credentialing handled: Platform manages insurance credentialing, state licensing support
• Technology included: Telehealth platform, EHR, e-prescribing all integrated
• Predictable economics: You know exactly what you’ll pay per patient vs. uncertain marketing ROI

The math is straightforward: Would you rather spend $3,000-5,000/month for 6-12 months with uncertain results, or pay a per-appointment fee and start seeing patients immediately with guaranteed ROI?

For most providers—especially those starting in telehealth or scaling an existing practice—the platform model simply makes more financial sense. You can always build your own brand on the side while using the platform for reliable patient flow.

Key Takeaways for Providers

For Psychiatrists:

• You can prescribe ADHD stimulants via telehealth in all 50 states right now (under federal flexibilities extended through 2025)
• You need state medical licenses wherever patients are located, DEA registration, and compliance with state PDMP/e-prescribing rules
• Your practice is unrestricted by scope—you don’t need supervision or collaboration with anyone
• Reimbursement is strong (parity with in-person care in most states)
• The regulatory environment may change in 2026, but telehealth prescribing in some form will likely continue

For PMHNPs:

• Your ability to prescribe ADHD stimulants depends entirely on your state
• In FPA states (NY, IL, CA post-experience), you can practice and prescribe like a psychiatrist once you meet experience requirements
• In restricted states (TX, FL, PA), you need physician collaboration and may face limits on what/how much you can prescribe
• Texas essentially prohibits NP outpatient stimulant prescribing; Florida and PA require physician involvement but allow it under supervision
• Check your state’s nurse practice act carefully and understand whether you’ll need an MD partner

For Everyone:

• Telehealth ADHD care is clinically effective, financially viable, and in high demand
• Patient acquisition through DIY marketing is expensive and risky ($200-500+ per patient with no guarantees)
• Platforms that provide pre-qualified patient flow, handle compliance, and charge per-appointment fees offer predictable ROI vs. marketing gambles
• The best protection against regulatory scrutiny is thorough documentation, proper evaluation, and conservative prescribing practices
• Provider shortages mean demand will remain high—now is a good time to enter or expand in this space

Next Steps: Getting Started in Telehealth ADHD Care

If you’re ready to start treating ADHD patients via telehealth, here’s your action plan:

1. Verify Your Current Scope

• Check your state’s current laws on NP/MD prescribing authority
• Confirm you’re licensed in states where you want to practice
• Ensure you have DEA registration and any required state controlled substance permits

2. Get Credentialed

• If going solo: Set up EPCS e-prescribing, PDMP access in your states, malpractice coverage
• If joining a platform: Complete credentialing process (usually 2-4 weeks)

3. Learn Your State’s Specific Requirements

• PDMP checking frequency
• E-prescribing mandates
• Telehealth consent/documentation requirements
• Any quantity limits or collaborative agreement rules (for NPs)

4. Set Up Your Clinical Workflow

• Choose your rating scales/assessment tools
• Create documentation templates that cover diagnostic criteria, risk assessment, informed consent
• Decide on your prescribing philosophy (starting doses, titration protocols, when to use non-stimulants)

5. Decide on Your Patient Acquisition Strategy

• DIY marketing: Budget $3,000-5,000/month minimum and plan for 6-12 month ramp-up
• Platform: Apply to join a network like Klarity Health that provides patient flow

6. Stay Informed on Regulatory Changes

• Subscribe to DEA and state medical board updates
• Join professional organizations (AACAP, APA, AANP) that track policy changes
• Have a contingency plan if in-person requirements return

The demand is there. The reimbursement is solid. The clinical work is straightforward if you follow good practices. What you need now is clarity on compliance and a smart strategy for patient acquisition that doesn’t drain your bank account with uncertain marketing spend.

Ready to start building your ADHD telehealth practice without the patient acquisition gamble? Learn more about joining Klarity Health’s provider network and getting matched with pre-qualified ADHD patients in your licensed states.

Frequently Asked Questions

Can I prescribe Adderall on the first telehealth visit?

Yes, under current federal flexibilities (extended through end of 2025). You can conduct an initial ADHD evaluation via video and prescribe stimulants without ever meeting the patient in person. However, you must conduct a thorough evaluation that meets the standard of care—don’t skip the diagnostic process just because it’s a first visit.

Do I need a separate DEA license for telehealth prescribing?

No. Your regular DEA registration covers telehealth prescribing as long as you’re complying with current rules. You need a DEA registration in each state where you’re prescribing (some states require separate state controlled substance registrations as well).

What happens if my patient moves to a different state mid-treatment?

If your patient relocates to a state where you’re not licensed, you legally cannot continue prescribing to them via telehealth. They’ll need to establish care with a provider licensed in their new state, or you’ll need to obtain licensure there. Some platforms help facilitate multi-state licensing for this reason.

Can I prescribe ADHD meds via phone-only (audio-only) visits?

This varies by state. Some states (like Texas) explicitly require video for controlled substance prescribing. Federal rules during COVID allowed audio-only for mental health services, but as we transition to permanent telehealth rules, video will likely be required for controlled substances. Best practice: use video whenever possible.

How often do I need to see ADHD patients for refills?

There’s no universal legal requirement, but standard of care typically means monthly visits initially while titrating dose, then every 2-3 months once stable. Since Schedule II prescriptions can’t have refills, you’ll need to write a new prescription each month anyway—most providers align visits with prescriptions.

What if a patient’s PDMP shows they’re getting controlled substances from multiple providers?

This is a red flag. You should discuss it with the patient (there may be legitimate explanations like recent doctor changes or specialists prescribing different meds). If you’re concerned about ‘doctor shopping’ or diversion, it’s appropriate to decline prescribing or require closer monitoring (more frequent visits, pill counts, urine screens). Document your decision-making process.

Can I treat children with ADHD via telehealth?

Yes, though you’ll need parental consent and may want collateral information from teachers or prior providers. The diagnostic process is similar but usually involves more extensive history gathering. Some insurers have specific requirements for pediatric telehealth visits. Check your state’s rules on treating minors via telemedicine.

What do I do during the Adderall shortage?

Have backup options ready: other stimulant formulations (methylphenidate instead of amphetamine salts), extended-release versions, or non-stimulants (Strattera, Wellbutrin, Qelbree). Help patients call multiple pharmacies to find stock. Consider compounding pharmacies in states where that’s allowed. Document your rationale for medication changes due to availability.

Do I need malpractice insurance that specifically covers telehealth?

Most malpractice policies now include telehealth in their standard coverage, but verify this with your carrier. Make sure your policy covers practice in all states where you’re licensed and treating patients. Some platforms provide malpractice coverage as part of their provider agreements.

How do I handle prior authorizations for ADHD meds in telehealth?

The same way you would in-person—insurers require prior auth for many brand-name stimulants and some dosages of generic medications. Most telehealth platforms integrate with prior auth services or have staff who handle these. Budget time for this administrative work, especially if you’re solo. Using generic medications when clinically appropriate reduces prior auth burden.

Sources & Verification

All regulatory and clinical information in this guide has been verified against current federal and state sources as of February 2026. Key sources include:

Federal Regulations:

• DEA COVID-19 telemedicine flexibilities (extended through December 31, 2025 per DEA/HHS joint announcement November 18, 2024)
• Ryan Haight Online Pharmacy Consumer Protection Act of 2008
• Controlled Substances Act Schedule II prescribing requirements

State Laws & Regulations:

• Florida Statutes §456.47 (telehealth prescribing) and §464.012 (APRN scope)
• Texas Medical Practice Act and Board of Nursing rules on prescriptive authority
• California AB 890 (NP independent practice, effective 2023)
• New York NP Modernization Act (Education Law §6902)
• Pennsylvania Nursing Code §21.284 (CRNP prescribing parameters)
• Illinois Nurse Practice Act 225 ILCS 65 (APRN Full Practice Authority)

Prescribing Authority Data:

• RxAgent ‘NP Prescriptive Authority by State (2026 Guide)’ (updated December 28, 2025)
• American Association of Nurse Practitioners state-by-state scope of practice maps
• State medical and nursing board regulations (accessed February 2026)

Workforce & Market Data:

• Health Resources & Services Administration (HRSA) shortage area designations
• Healing Psychiatry Florida ‘Psychiatrist Shortage by State – 2026 Report’ (January 15, 2026)
• State-specific psychiatrist-to-population ratios from multiple sources

Reimbursement Information:

• CMS Medicare Physician Fee Schedule (2025-2026)
• Therathink ‘Insurance Reimbursement Rates for Psychiatrists [2026]’
• State Medicaid reimbursement schedules
• BehaveHealth telehealth parity analysis (2024-2026)

Policy & News Sources:

• Axios health policy reporting (September-November 2024)
• Associated Press health coverage on ADHD prescribing trends (January 2024)
• Center for Connected Health Policy (CCHP) state telehealth law database (updated January 19, 2026)
• Texas Legislature bill analyses (88th session, 2023)

All information reflects laws

Source:

• https://www.axios.com/2024/09/18/telehealth-services-controlled-substances-congress#:~:text=Why%20it%20matters%3A%20Pandemic,end%20of%20this%20year%20after
• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20and,the%20third%20temporary%20extension%20of
• https://www.flsenate.gov/Laws/Statutes/2023/456.47#:~:text=,is%20prescribed%20for%20the%20following
• https://www.flsenate.gov/Laws/Statutes/2023/456.47#:~:text=1,disorder
• https://rxagent.co/blog/np-prescribing-authority#:~:text=OK%20%20,day%20%28ongoing%29%20%5B3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=TN%20%20,NP%3A%20Independent%20%5B3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=match%20at%20L210%20NY%20,terminal%20illness%2C%20MD%20initiation
• https://rxagent.co/blog/np-prescribing-authority#:~:text=ID%20%20,3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=FL%20%20,NP%3A%20Independent%20%5B3
• https://www.leg.state.fl.us/STATUTeS/index.cfm?Appmode=DisplayStatute&Search_String=&URL=0400-0499%2F0464%2FSections%2F0464.012.html#:~:text=also%20limit%20the%20prescribing%20of,shall%20adopt%20by%20rule%20the